Serum Levels of CA15-3, AFP, CA19-9 and CEA Tumor Markers in Cancer Care and Treatment of Patients with Impaired Renal Function on Hemodialysis

  • Estakhri, Rasoul (Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences) ;
  • Ghahramanzade, Ali (Department of Pathology, Faculty of Medicine, Tabriz University of Medical Sciences) ;
  • Vahedi, Amir (Department of Pathology, Faculty of Medicine, Tabriz University of Medical Sciences) ;
  • Nourazarian, Alireza (Laboratory of Imam Reza Training and Research Hospital, Tabriz University of Medical Sciences)
  • Published : 2013.03.30


Since renal failure causes decrease in tumor marker excretion, use of these markers in cancer care and treatment in patients with renal insufficiency or hemodialysis is controversial. The aim of this study was to investigate differences of serum levels of tumor markers CA15-3, AFP, CA19-9 and CEA in patients with impaired renal function. A total of 100 patients referred to the Tabriz Immam Reza and Amiralmomenin hospital from June 2010 to November 2011 were selected for study. Subjects were divided to 3 groups of healthy, dialysis and renal failure but non hemodialysis cases, the last category being re-grouped based on creatinine clearance. No significant relationship between different groups in serum levels of CEA (P=0.99) and CA19-9 (P=0.29) tumor markers was found. A significant correlation was observed between serum levels of AFP (P<0.001) and CA15-3 (P<0.001) and also a tendency between creatinine clearance and CEA (r=0.05, P=0.625). Creatinine clearance significantly correlated with AFP (P<0.001, r=0.53) and CA15-3 (p=0.00, r=-0.412), but not CA19-9 (P=0.089, r=-0.171). According to results of this study it appears that use of tumor markers in patients with impaired renal function should be performed with special precautions.


  1. Arican A, Ozdemir N, Sezer S, et al (1999). Tumor markers in hemodialysis patients. Transplantation Proceedings, 31, 3367-8.
  2. Arik N, Adam B, Akpolat T, Haşil K, Tabak S (1996). Serum tumour markers in renal failure. Int Urology and Nephrology, 28, 601-4.
  3. Cases A, Filella X, Molina R, et al (1991). Tumor markers in chronic renal failure and hemodialysis patients. Nephron, 57, 183-6.
  4. Danisman A, Kilic S, Kukul E, et al (2000). Do renal failure and hemodialysis have any effect on the elimination of free and total prostate-specific antigen? Eur Urology, 37, 579-81.
  5. Djavan B, Shariat S, Ghawidel K, et al (1999). Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: is prostate cancer detection compromised in patients receiving long-term dialysis? Urology, 53, 1169-74.
  6. Engin H, Borazan A, Aydemir S, Yilmaz A (2007). Assessment of tumor markers in patients with chronic renal failure. Tur J Cancer, 37, 143.
  7. Filella X, Cases A, Molina R, et al (1990).Tumor markers in patients with chronic renal failure. Int J Biol Markers, 5, 85-8.
  8. Jiang M, Pu R (2010). Study on serum tumor related material (BXTM) with early diagnosis in malignant tumor. National Med Frontiers of China, 5, 80-1.
  9. Lye WC, Tambyah P, Leong SO, Lee EJ (1994). Serum tumor markers in patients on dialysis and kidney transplantation. Adv Perit Dial, 10, 109-11.
  10. Odagiri E, Jibiki K, Takeda M, et al (1991). Effect of hemodialysis on the concentration of the seven tumor markers carcinoembryonic antigen, alpha-fetoprotein, squamous cell carcinoma-related antigen, neuron-specific enolase, CA 125, CA 19-9 and CA 15-3 in uremic patients. Am J Nephrology, 11, 363-8.
  11. Polenakovic M, Sikole A, Dzikova S, Polenakovic B, Gelev S (1997). Acquired renal cystic disease and tumor markers in chronic hemodialysis patients. Int J Artificial Organs, 20, 96-100.
  12. Rampino T, Gregorini M, Dal Canton A ( 2009). Scatter factors in renal disease: Dr. Jeckyll and Mr. Hyde? Cytokine & Growth Factor Reviews, 20, 77-85.
  13. Richard AM, Matthew RP (2007). Henty's clinical diagnosis and management by laboratorymethods. 21 ed.
  14. Shu J, Li CG, Liu YC, et al (2012). Comparison of serum tumor associated material (TAM) with conventional biomarkers in cancer patients. Asian Pac J Cancer Prev, 13, 2399-403.
  15. Tzitzikos G, Saridi M, Filippopoulou T, et al (2010). Measurement of tumor markers in chronic hemodialysis patients. Saudi J Kidney Diseases and Transplantation, 21, 50-3.
  16. Visser CE, Brouwer-Steenbergen JJ, Betjes MG, et al (1995). Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Nephrology Dialysis Transplantation, 10, 64-9.
  17. Walz G, Kunzendorf U, Keller F, Fitzner R, Offermann G (1988). Elevated tumor markers in hemodialysis patients. Am J Nephrology, 8, 187-9.
  18. Xiaofang Y, Yue Z, Xialian X, Zhibin Y (2007). Serum tumour markers in patients with chronic kidney disease. Scand J Clin Lab Invest, 67, 661-7.

Cited by

  1. Awareness of Cancer Screening During Treatment of Patients with Renal Failure: A Physician Survey in Turkey vol.15, pp.5, 2014,
  2. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline vol.33, pp.24, 2015,
  3. Characteristics and Prognosis of Hepatocellular Carcinoma in Japanese Patients Undergoing Dialysis vol.21, pp.5, 2017,